Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

Texas Alzheimer's Disease Research and Care Consortium

doi:10.1016/j.dadm.2015.08.001

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

Texas Alzheimer's Disease Research and Care Consortium

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.

Original language	English (US)
Pages (from-to)	464-471
Number of pages	8
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	1
Issue number	4
DOIs	https://doi.org/10.1016/j.dadm.2015.08.001
State	Published - Dec 1 2015

Keywords

Alzheimer's disease
Biomarkers
Dementia
Homocysteine
Lp-PLA2

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1016/j.dadm.2015.08.001

Cite this

@article{e59e8942eb6544e3a6c960e6717aad67,

title = "Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease",

abstract = "Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.",

keywords = "Alzheimer's disease, Biomarkers, Dementia, Homocysteine, Lp-PLA2",

author = "{Texas Alzheimer's Disease Research and Care Consortium} and Doody, {Rachelle S.} and Jasenka Demirovic and Ballantyne, {Christie M.} and Wenyaw Chan and Robert Barber and Suzanne Powell and Valory Pavlik and Susan Rountree and Paul Massman and Eveleen Darby and Tracy Evans and Aisha Khaleeq and Gregory Schrimsher and Andrew Dentino and Ronnie Orozco and Thomas Fairchild and Janice Knebl and O'Bryant, {Sid E.} and Hall, {James R.} and Douglas Mains and Lisa Alvarez and Erin Braddock and Rosemary McCallum and Leigh Johnson and Perrie Adams and Roger Rosenberg and Myron Weiner and Benjamin Williams and Mary Quiceno and Joan Reisch and Ryan Huebinger and Guanghua Xiao and Doris Svetlik and Amy Werry and Janet Smith and Donald Royall and Raymond Palmer and Marsha Polk",

note = "Funding Information: The authors acknowledge that this project was supported by the Texas Alzheimer's Research and Care Consortium (TARCC) funded by the State of Texas through the Texas Council on Alzheimer's Disease and Related Disorders . Publisher Copyright: {\textcopyright} 2015 The Authors.",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/j.dadm.2015.08.001",

language = "English (US)",

volume = "1",

pages = "464--471",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

AU - Texas Alzheimer's Disease Research and Care Consortium

AU - Doody, Rachelle S.

AU - Demirovic, Jasenka

AU - Ballantyne, Christie M.

AU - Chan, Wenyaw

AU - Barber, Robert

AU - Powell, Suzanne

AU - Pavlik, Valory

AU - Rountree, Susan

AU - Massman, Paul

AU - Darby, Eveleen

AU - Evans, Tracy

AU - Khaleeq, Aisha

AU - Schrimsher, Gregory

AU - Dentino, Andrew

AU - Orozco, Ronnie

AU - Fairchild, Thomas

AU - Knebl, Janice

AU - O'Bryant, Sid E.

AU - Hall, James R.

AU - Mains, Douglas

AU - Alvarez, Lisa

AU - Braddock, Erin

AU - McCallum, Rosemary

AU - Johnson, Leigh

AU - Adams, Perrie

AU - Rosenberg, Roger

AU - Weiner, Myron

AU - Williams, Benjamin

AU - Quiceno, Mary

AU - Reisch, Joan

AU - Huebinger, Ryan

AU - Xiao, Guanghua

AU - Svetlik, Doris

AU - Werry, Amy

AU - Smith, Janet

AU - Royall, Donald

AU - Palmer, Raymond

AU - Polk, Marsha

N1 - Funding Information: The authors acknowledge that this project was supported by the Texas Alzheimer's Research and Care Consortium (TARCC) funded by the State of Texas through the Texas Council on Alzheimer's Disease and Related Disorders . Publisher Copyright: © 2015 The Authors.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.

AB - Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.

KW - Alzheimer's disease

KW - Biomarkers

KW - Dementia

KW - Homocysteine

KW - Lp-PLA2

UR - http://www.scopus.com/inward/record.url?scp=84949563915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949563915&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2015.08.001

DO - 10.1016/j.dadm.2015.08.001

M3 - Article

AN - SCOPUS:84949563915

VL - 1

SP - 464

EP - 471

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

IS - 4

ER -

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this